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Abstract: In this study, the authors constructed a novel PLGA [poly(D,L-lactic-co-glycolic 
acid)]-based polymeric nanocarrier co-encapsulated with doxorubicin (DOX) and magnetic 
Fe3O4   nanoparticles (MNPs) using a single emulsion evaporation method. The DOX-MNPs 
showed high entrapment efficiency, and they supported a sustained and steady release of DOX. 
Moreover, the drug release was pH sensitive, with a faster release rate in an acidic environment 
than in a neutral environment. In vitro, the DOX-MNPs were easily internalized into murine 
Lewis lung carcinoma cells and they induced apoptosis. In vivo, the DOX-MNPs showed higher 
antitumor activity than free DOX solution. Furthermore, the antitumor activity of the DOX-
MNPs was higher with than without an external magnetic field; they were also associated with 
smaller tumor volume and a lower metastases incidence rate. This work may provide a new 
modality for developing an effective drug delivery system.
Keywords: antitumor activity, external magnetic field, intratumoral injection, apoptosis, Lewis 
lung carcinoma
Introduction
Doxorubicin (DOX) is an anthracycline glycoside antibiotic originally produced by 
Streptomyces peucetius var. caesius.1 DOX exerts its cytotoxic effect as a DNA-
intercalating agent to inhibit further DNA and RNA biosynthesis.2 Thus, DOX is 
widely used either as a single agent or in combination with other chemotherapeutic 
regimens for various kinds of solid tumors.3,4 However, dose-limiting toxic side effects 
such as cardiotoxicity, myelosuppression, mucositis, and alopecia limit the clinical 
application of DOX, owing to nonspecific distribution to healthy normal tissues.5 As 
a result, studies over the past few decades have focused on the development of drug 
delivery systems and administration routes for DOX to increase tissue selectivity and 
improve its toxicity profile.6–8
Intratumoral administration of chemotherapeutic agents is a potentially more 
effective modality to overcome the described limitation and this has been extensively 
evaluated using a number of anticancer drugs.9,10 Such targeted delivery may realize 
drug localization within the tumor tissue and divert the drug from nontarget organs 
to improve toxicity and increase efficacy, while decreasing the incidence and the 
intensity of side effects.
Although intratumoral administration is a promising approach for the treatment 
of various solid tumors with minimal systemic toxicity, its efficacy is highly depen-
dent on the timing and frequency of the drug injections because of its rapid clear-
ance from the tumor site. It is proposed that a drug delivery system is required to 
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ensure the drug is properly localized and that it is released 
in a controlled way.11 Several polymeric drug delivery sys-
tems have been developed for intratumoral drug delivery, 
including hydrogels,9 microparticles,10 nanoparticles,12 and 
nanofibers.13
Magnetic nanoparticles (MNPs) have been investigated 
for decades in drug delivery systems because of their 
high  magnetic  responsiveness,  biodegradability, 
biocompatibility, high delivery efficiency and potential 
targeting function.14–16 Moreover, iron oxide nanoparticles 
are the only MNPs approved for clinical use by the US 
Food and Drug   Administration.17 However, most of the 
MNP drug delivery systems were developed for systemic 
  administration, which caused severe side effects and 
  inevitable uptake by the reticuloendothelial system (RES).18 
In the present study, the authors propose that combining 
  intratumoral administration with a MNP drug delivery 
  system may   provide opportunities for treating cancers in 
a safe and effective manner. The drug-loaded MNPs are 
directly injected into solid tumors; they are expected to be 
held in place by an external magnetic field and to release 
the drug in a controlled manner.
The authors aimed to develop a MNP drug delivery 
system for intratumoral administration. A single emulsion 
evaporation method with magnetic Fe3O4 cores and a shell of 
biocompatible polymeric PLGA [poly(D,L-lactic-co-glycolic 
acid)] was used to prepare the MNPs. The physicochemical 
properties of the DOX-loaded MNPs (DOX-MNPs) were 
characterized in terms of morphology, size distribution, 
and drug loading content. In vitro release profiles of DOX 
from DOX-MNPs were examined in both acidic and neutral 
environments. The in vitro anticancer activity of DOX-MNPs 
was determined using a Lewis lung carcinoma (LLC) cell 
line, and the apoptotic rate was analyzed by flow cytometry. 
The uptake of nanoparticles by the LLC cells was visual-
ized using confocal microscopy. Finally, in vivo antitumor 
activity was assessed by a single intratumoral injection of 
DOX-MNPs into C57BL/6 mice bearing subcutaneously 
established LLC.
Material and methods
Cell line and cell culture
The murine LLC cells were a gift from Dr Kangla Zong in 
the Stanford University Medical Center (Stanford, CA). The 
human osteosarcoma OS-732 cells were purchased from 
the Beijing Jishuitan Hospital (Beijing, People’s Republic 
of China). The murine-leukemic monocyte-macrophage 
cell line (RAW 264.7) was purchased from the American 
Type Culture Collection (Manassas, VA). The cell culture 
medium and the fetal bovine serum were obtained from 
Invitrogen (Carlsbad, CA). The culture flasks and dishes 
were from Corning (New York, NY). The cells were cul-
tured in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% heat-inactivated fetal bovine 
serum (Invitrogen), penicillin (100 U/mL) (Invitrogen), 
and streptomycin (100 U/mL) (Invitrogen), and the medium 
was replaced twice a week. The cultures were maintained 
at 37°C in a humidified atmosphere containing 5% carbon 
dioxide.
Synthesis of Fe3O4 nanoparticles
The synthesis of aqueous Fe3O4 nanoparticles was based 
on coprecipitation of Fe (II) and Fe (III) salts by ammo-
nium hydroxide (NH4OH) at 60°C. In a typical procedure 
to obtain Fe3O4 precipitate (1 g), FeCl2 ⋅ 4H 2O (0.86 g) and 
FeCl3 ⋅ 6H 2O (2.35 g) were dissolved in deionized water 
(40 mL) with vigorous stirring, such that Fe3+/Fe2+ = 2. 
When the solution was heated to 80°C, vigorous stirring was 
continued for another 30 minutes under a stream of nitrogen, 
then a solution of oleic acid (100 mg) in acetone (5 mL) was 
added to the flask, followed by 5 mL of ammonia solution 
(25% NH4OH) introduced by syringe. After 10 minutes, 
oleic acid (1 g) was added drop-wise to the suspension 
and with constant stirring over a 30-minute period. After 
being heated for an additional 30 minutes, the magnetic 
particles were precipitated by drop-wise addition of a 2 M 
hydrochloric acid solution and then washed five times with 
acetone to remove the excess oleic acid. A total of 30 mL 
of the ammonia solution (18% NH4OH) and 1 g of oleic 
acid were added to disperse the magnetic precipitates. The 
solution had nitrogen bubbled through it and was heated 
to 80°C for 30 minutes. Finally, the magnetic fluids were 
stored in an atmosphere of nitrogen.
Preparation of DOX-MNPs
MNPs containing oleic acid-coated Fe3O4   nanoparticles 
and DOX hydrochloride (Taizhou, Zhejiang Hisun 
  Pharmaceutical Co, Ltd, China) were prepared by the 
conventional oil-  in-water single emulsion evaporation 
method. Three equivalents of triethylamine were added to 
an aqueous solution of DOX hydrochloride (5 mg/mL), and 
the drug was then extracted to prepare a methylene chloride 
solution of  DOX. Initially, synthesized nanoparticles were 
dispersed in methylene chloride, and the resulting disper-
sion was mixed with the methylene chloride solution of 
DOX. PLGA (20 mg) was added to the solution of oleic 
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acid-coated Fe3O4 nanoparticles and DOX (1 mL). This 
mixture was emulsified in aqueous solution (100 mL) of 
Pluronic F-127 (7 wt %) by use of a probe-type   sonicator 
at 600 W for 10 minutes in an ice bath. The resulting sus-
pension was stirred for 12 hours at room temperature to 
evaporate the organic solvent and was then centrifuged at 
10,000 rpm for 10 minutes. The precipitate was washed 
twice in water to remove the remaining Pluronic F-127 and 
free PLGA. The supernatant was used for the analysis of 
DOX loading efficiency.
For evaluation of drug contents and drug loading 
  efficiency, freeze-dried DOX-MNPs (5 mg) were dis-
solved in dimethyl sulfoxide (10 mL). The DOX con-
centration was evaluated using an ultraviolet and visible 
spectrophotometer (UV-1201;   Shimadzu, Kyoto, Japan) 
at 480 nm. Empty nanoparticles of PLGA were used as 
a blank test.
Loading contents = (  Drug weight in the nanoparticles 
/Weight of nanoparticles) × 100%  (1)
Encapsulation efficiency =   (Residual drug in the   nanoparticle 
/Initial feeding amount of drug) 
× 100%  (2)
Physicochemical properties  
of DOX-MNPs
The size and morphologic features of DOX-MNPs were 
examined using dynamic light scattering and transmis-
sion electron microscopy. DOX-MNPs were diluted to 
a concentration of 1 mg/mL with deionized water. The 
DOX-MNPs were stained with 1% uranyl acetate and 
examined with a JEOL 100 CX electron microscope 
(JEOL USA, Inc, Peabody, MA). DOX-MNP size was 
determined with a Zetasizer 5000 (Malvern Instruments 
Ltd, Malvern, UK).
To determine the kinetics of in vitro release of DOX 
from DOX-MNPs, freeze-dried DOX-MNPs (1 mg) were 
transferred to a dialysis tube (MEMBRA-CEL®, MW cutoff, 
12000; Viskase Companies, Inc, Darien, IL), and the sealed 
tube was introduced into a vial containing 10 mL of either 
phosphate buffered saline (PBS) (pH 7.4) or acetate buffer 
(pH 5.0). The vials were shaken horizontally in a shaking 
water bath (100 rpm) at 37°C for 168 hours. At predetermined 
time intervals, 2 mL samples of the medium were collected 
and replaced with the same amount of fresh medium. The 
amount of released DOX was analyzed by measuring the 
absorbance of the sample at 488 nm with the ultraviolet and 
visible spectrophotometer.
Cellular uptake of DOX-MNPs
LLC, OS-732, and RAW 264.7 cells were plated on 14 mm2 
glass coverslips that were placed in six-well plates at the 
  density of 5 × 105 cells/well; to allow cell attachment, 
these were cultured at 37°C for 24 hours in an atmosphere 
containing 5% carbon dioxide. DOX-MNPs or free DOX 
were diluted with culture medium to 5 µg/mL, followed 
by coculture with aforementioned cell lines for 30, 60, and 
120 minutes. The uptake experiment was terminated at each 
time point by aspirating the test samples and washing the cell 
monolayers with ice-cold PBS three times. Each cell mono-
layer on the coverslips was then fixed with methanol-acetone 
(1:1, v/v), followed by nuclear staining with Hoechst 33258 
and examination under fluorescence microscopy. The uptake 
of DOX-MNPs or free DOX can be visualized by virtue of 
the intrinsic red fluorescence of DOX. Fluorescence intensity 
was analyzed on a fluorescence microscope (Eclipse E800; 
Nikon, Tokyo, Japan) at a wavelength of 488 nm.
Analysis of apoptosis using Annexin V 
and propidium iodide staining by flow 
cytometry
Apoptotic cells were identified with fluorescein 
  isothiocyanate-labeled Annexin V (Annexin V-FITC). 
  Propidium iodide (PI) (BioVision, Mountain View, CA), 
a dead cell marker, was also used as a stain, and according 
to the manufacturer’s protocol. LLC cells were plated at 
5 × 105 cells per well in DMEM (2 mL) in six-well plates 
and grown for 24 hours. The medium was then replaced 
with a series of concentrations of DOX-MNPs (1, 5, 
and 10 µg/mL) for 48 hours. All drugs were diluted with 
DMEM, and cells treated with DMEM alone were used as 
a control. Briefly, treated cells were harvested, trypsinized, 
washed with PBS, incubated with Annexin V-FITC and PI 
for 15 minutes at room temperature in the dark, and analyzed 
on a FACSCalibur flow cytometer (Becton, Dickinson 
and Company, Mountain View, CA) with data acquisition 
software (CellQuest; Becton, Dickinson and Company).
In vivo antitumor activity  
in a murine model
Female C57BL/6 mice (6 weeks old) were obtained from 
the Institute of Materia Medica, Chinese Military   Academy 
of Medical Sciences (Beijing, People’s Republic of China). 
All animal procedures in this study followed the   protocol 
approved by the Institutional Animal Care and Use 
  Committee of the Chinese Academy of Sciences.
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Murine LLC cells (about 5 × 105 cells per 0.2 mL) 
were implanted subcutaneously into the backs of the 
mice. When the tumor volumes reached 5 × 5 × 4 mm, 
60 tumor-bearing mice were randomly assigned to one 
of the following six   treatment groups (n = 10 per group): 
(1) DOX-MNPs (10 mg/kg, single dose) with an external 
magnetic field; (2) DOX-MNPs only (10 mg/kg, single 
dose); (3) MNPs (107.6 mg/kg, single dose) with an exter-
nal magnetic field; (4) MNPs alone (107.6 mg/kg, single 
dose); (5) free DOX solution (10 mg/kg, single dose); and 
(6) control (0.9% sodium chloride). All drugs were diluted 
with 0.9% sodium chloride (100 µL), and all were admin-
istered through direct intratumoral injection. After drug 
administration, mortality was monitored daily and tumor 
growth was determined by caliper measurement at 3-day 
intervals over 14 days. Tumor volume was calculated as 
follows:
  Tumor volume (mm3) = (Length × Width2)/2  (3)
For the treatment groups with an external magnetic field, 
a disk magnet with a magnetic field strength of 0.5 tesla 
(neodymium iron boron, 10 mm diameter, 2 mm thickness) 
was fixed onto the skin above the tumor immediately after 
the drug was injected into the tumor, and the magnet was 
held in place for 48 hours.
Histological examination
After the mice were sacrificed, the tumors, hearts, livers, 
spleens, lungs, and kidneys were immediately harvested, 
weighed, fixed in 10% formalin, and embedded in   paraffin. 
Sections were observed by light microscopy after they 
had been stained with hematoxylin and eosin and Perls’ 
  Prussian blue.
Statistical analysis
All data were analyzed with SPSS software (v 13.0; SPSS 
Inc, Chicago, IL). Results are presented as mean plus or 
minus standard deviation. The two-way analysis of vari-
ance and Student’s t-test were used to compare data from 
different treatment groups, and differences were considered 
significant at P , 0.05.
Results
Physicochemical properties  
of DOX-MNPs
The DOX-MNPs containing magnetic Fe3O4 cores and 
DOX were prepared using an oil-in-water emulsion and a 
  subsequent solvent evaporation method. The morphologic 
features observed by transmission electron microscopy 
showed that the size distribution (in diameter) of the MNPs 
was between 4 and 6 nm (Figure 1A) and the size distribu-
tion of DOX-MNPs was generally between 200 and 300 nm 
(Figure 1B). The Zetasizer showed a narrow particle size 
distribution, with an average diameter of about 280 nm 
(Figure 1C). The DOX-MNPs showed excellent magnetic 
responsiveness and dispersibility in aqueous solution: they 
were easily dispersed in water and could be drawn from the 
aqueous solution by a permanent magnet (Figure 1D).
Encapsulation efficiency
Encapsulation efficiency was defined as the weight percent-
age of DOX incorporated into DOX-MNPs. When the weight 
ratio of DOX to PLGA was 20 µg/mg, the encapsulation 
efficiency was approximately 90%. The loading content was 
85 µg/mg.
Drug release profile in vitro
The in vitro release of DOX from the DOX-MNPs showed 
a sustained release pattern under neutral (pH 7.4) and acidic 
(pH 5.0) conditions. The drug release from DOX-MNPs was 
much slower at pH 7.4 than at pH 5.0. After 7 days of incu-
bation, approximately 65% of the total drug was released in 
pH 5.0 conditions, in comparison with a 25% release rate in 
pH 7.4 conditions (Figure 2).
Cellular uptake of DOX-MNPs
DOX-MNPs were added to LLC, OS-732, and RAW 
264.7 cells, and were then incubated separately for 
30, 60, and 120 minutes. The cells were collected for 
analysis of intrinsic fluorescence of DOX by fluorescence 
  microscopy. LLC (Figure 3A), OS-732 (Figure 3B), and 
RAW 264.7 cells (Figure 3B) internalized DOX-MNPs at 
each time point.
DOX-MNPs-induced apoptosis  
of tumor cells
The percentage of apoptotic and necrotic cells was quantified 
by Annexin V-FITC and PI assay in LLC cells. The LLC 
cells were treated with fresh medium containing three dif-
ferent concentrations of DOX-MNPs (1 µg/mL, 5 µg/mL, 
and 10 µg/mL). The dead cells increased in proportion 
to dosage (Figure 4A and B). To compare the apoptosis 
activity of DOX-MNPs and free DOX on tumor cells, LLC 
cells were exposed to free DOX (5 µg/mL) or equivalent 
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concentrations of DOX-MNPs for 48 hours. The percent-
age of dead cells in the DOX-MNPs (80%) was higher than 
in the free DOX (29%), whereas the percentage of necrotic 
cells in untreated and MNP-treated cells was less than 20% 
(Figure 4C and D).
Antitumor effect of DOX-MNPs in vivo
The authors compared the antitumor effect of DOX-MNPs 
with or without an external magnetic field and free DOX in 
the subcutaneous tumor model of LLC. On day 14, the aver-
age tumor size in the saline control group was 2.311 cm3, in 
the group receiving free DOX alone it was 1.911 cm3, in the 
group receiving DOX-MNPs it was 1.498 cm3, and in the 
group receiving DOX-MNPs with an external magnetic field 
it was 1.027 cm3. The sizes with MNPs alone and MNPs with 
external magnetic field treatment were 2.212 and 2.295 cm3, 
respectively. The tumor size in mice receiving DOX-MNPs 
with an external magnetic field was significantly smaller than 
in the control mice (P = 0.027). The tumor growth curve is 
shown in Figure 5. Tumor growth rates in mice treated with 
DOX-MNPs and an external magnetic field were significantly 
decreased, whereas free DOX treatment only slightly reduced 
the tumor growth.
There was no weight loss observed in the mice, 
  including the mice treated with DOX-MNPs and an external 
magnetic field.
There were no lesions in the main organs, including the 
heart, liver, lungs, pancreas, and kidneys. Tumor metastasis 
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Figure 2 In vitro release profile of doxorubicin (DOX) from DOX-loaded magnetic 
Fe3O4 nanoparticles at pH 5.0 in acetate buffer and pH 7.4 in phosphate buffered saline. 
Note: The results presented show the average from three measurements.
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was found in the lungs, kidneys, and, occasionally, liver and 
heart. The incidence of metastasis was highest in the control 
group and lowest in the group receiving DOX-MNPs with 
an external magnetic field (Table 1).
The penetration of tumors and organs by the MNPs was 
analyzed by hematoxylin and eosin and Perls’ Prussian blue 
staining. The blue-stained cells were found in tumor cells in 
groups receiving Fe3O4 treatment (Figure 6A and B), and in 
some lung metastasis tumor cells (Figure 6C), but not in the 
saline control or free DOX-treated tumor cells. The Fe3O4-
positive tumor cells were more abundant in the groups treated 
with an external magnetic field than those treated with MNPs 
only (Figure 6A and B). In the groups treated with MNPs, 
Fe3O4 was deposited in the kidney tubule in a couple of cases 
(one in the DOX-MNP group and one in the MNP group) and, 
(although only occasionally) under the capsule of the spleen in 
one case (in the MNP group). However, no Fe3O4 was deposited 
in the groups treated with an external magnetic field.
Discussion
The intratumoral administration of anticancer drugs   represents 
a growing trend for maximizing local tumor control with 
Figure 3 Observation of cellular uptake of doxorubicin-loaded magnetic Fe3O4 nanoparticles (DOX-MNPs) by different cell types after 30, 60, and 120 minutes of incubation 
under a fluorescence microscope. Overlaid images show nuclear staining with Hoechst 33258 (blue) and DOX-derived fluorescence (red). (A) Cellular uptake of free DOX 
and DOX-MNPs by Lewis lung carcinoma cells; (B) cellular uptake of DOX-MNPs by human osteosarcoma OS-732 cells and RAW 264.7 cells (murine-leukemic monocyte-
macrophage cell line).
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minimal systemic toxicity; however, it requires a novel 
drug   delivery system for treatment efficacy and ease of 
  administration. MNPs have been widely used in the delivery 
of chemotherapeutics, achieving promising results.19–23 The 
authors propose that combining intratumoral administra-
tion with a magnetic nanocarrier in chemotherapy provides 
  opportunities for treating cancers in a safe and effective man-
ner. In this study, the authors fabricated a MNP drug delivery 
system for intratumoral administration that was comprised of 
magnetic Fe3O4 cores and a shell of   biocompatible   polymeric 
PLGA by a single emulsion evaporation method. The 
  DOX-MNPs showed high loading content and encapsulation 
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efficiency, and they supported a sustained and steady release 
of DOX. In vitro, the DOX-MNPs were easily internalized 
into tumor cells and they induced apoptosis. In vivo, the 
DOX-MNPs showed higher antitumor activity than the free 
DOX solution.
Systemic chemotherapy against cancers such as breast, 
prostate, lung, and gastrointestinal cancers can cause severe 
side effects because of the toxicity of the anticancer drugs 
on normal tissues. Moreover, the efficacy of anticancer 
drugs can be diminished because of rapid clearance from 
the circulation and poor distribution to the target tumor.24,25 
Intravenously injected free DOX was exposed to rapid 
elimination by the RES, mainly in the liver and spleen.26 
Even long-circulating formulations of free DOX were not 
capable of achieving tumor exposure to DOX for more than 
180 hours.27 An intratumoral injection of chemotherapeutic 
agents is potentially a more effective alternative to systemic 
administration, because direct delivery of the anticancer 
drug to the target may improve both the stability and 
the efficacy of anticancer drugs.28 Such targeted delivery 
would be expected to provide a high local concentration of 
agents, reducing systemic drug levels and thereby decreas-
ing the incidence of side effects compared with traditional 
treatments.
The size of the nanoparticles is a key parameter that 
determines its properties, application and fate. First, given 
that the smallest capillaries in the body are about 4 µm, 
particles larger than 4 µm will most likely become trapped 
in the lungs.17 Particles smaller than that will usually be 
eliminated by the mononuclear phagocytes system, a part 
of the body’s immune system also known as the RES. 
These involve the family of cells (primarily monocytes and 
macrophages) that are extensively distributed in the liver 
(Kupffer cells), spleen, bone marrow, and lymph nodes. 
Because of the greater accessibility, the macrophages in 
the liver and spleen will take up most of the particles. After 
intravenous administration, particles larger than 200 nm are 
usually sequestered by the spleen, as a result of mechani-
cal filtration.29 These particles are eventually removed by 
the cells of the phagocyte system,29 resulting in decreased 
blood circulation times. On the other hand, particles smaller 
than 10 nm are rapidly removed through extravasations and 
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renal clearance.29,30 Particles ranging from 10 to 100 nm are 
optimal for systemic administration and demonstrate the 
most prolonged blood circulation times.31 The particles in 
this size range are small enough to both evade the RES and 
penetrate the very small capillaries within the body tissues, 
and therefore they may offer the most effective distribution in 
certain tissues. Attempts have been made to retard the action 
of the RES and increase the half-life in the blood stream, such 
as by reducing the particle size and surface modification.32 
However, despite all efforts, complete evasion of the RES 
does not seem feasible, and unwanted migration to normal 
tissues in the body could cause toxic side effects.
One advantage of drug delivery systems using MNPs 
is the controlled drug release, which improves the drug 
Table 1 Metastasis of Lewis lung carcinoma in mice after treatment
Treatment Mice (n) Lung Kidney Liver Heart Total 
metastasis 
rate
Large Medium Small Large Small Small Medium
Dox-MNPs-magnet 8 2 0 1 1 0 0 0 50.0% (4/8)
Dox-MNPs 10 2 2 2 1 0 1 0 60.0% (6/10)
MNPs-magnet 6 1 1 2 1 0 0 0 66.7% (4/6)
MNPs 7 3 2 1 2 0 0 0 85.7% (6/7)
DOX 9 2 1 1 3 1 0 1 66.7% (6/9)
Control 8* 4 2 1 1 0 0 0 87.5% (7/8)
Note: *Some mice specimens were not included because the autopsy had not been performed immediately after the mouse was sacrificed.
Abbreviations: DOX, doxorubicin; magnet, external magnetic field; MNPs, magnetic Fe3O4 nanoparticles.
Hematoxylin & Eosin (H&E) Perls prussian blue
A
B
C
Figure 6 Histological analysis of the uptake of doxorubicin-loaded magnetic Fe3O4 nanoparticles (DOX-MNPs) in tumors (blue indicated the presence of iron): (A) marked 
accumulation of DOX-MNPs was observed in tumor cells with an external magnetic field; (B) less accumulation of DOX-MNPs in tumor cells without an external magnetic 
field; (C) accumulation of DOX-MNPs in lung metastasis of Lewis lung carcinoma.
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bioavailability and reduces the side effects and toxicity to 
healthy tissues. Because of its excellent biocompatibility 
and biodegradability, PLGA has been widely employed as 
a matrix material for preparation of nanoparticles for drug, 
gene, or imaging agent delivery. Changing the comonomer 
composition and molecular weight of PLGA can control 
the drug release rate from PLGA nanoparticles.33 Since 
the acidic pH is now regarded as a phenotype of the 
growth and invasiveness of solid tumors,34,35 developing 
pH-sensitive delivery systems seems to be a promising 
approach for   chemotherapy. In the present study, the DOX 
release rate from PLGA nanoparticles was higher at the 
acidic pH (pH 5.0) than at the neutral pH (pH 7.4), which 
may lead to increased accumulation of DOX in tumor 
cells and thereby adding therapeutic efficiency to the 
delivery system.
After delivery to the tumor site, the next important 
step is internalization into the tumor cell. This is directly 
related to the cytotoxicity of the drug, because the most 
commonly used chemotherapeutic drugs such as DOX 
and paclitaxel only show their antitumor efficiency when 
they bind to DNA or inhibit microtubule disassembly.36 In 
this study, the authors found the DOX-MNPs was readily 
taken up by LLC, OS-732, and RAW 264.7 cells, with a 
higher rate of cellular uptake and of larger amount than free 
DOX. In fact, the nanoparticles allow for efficient uptake 
by a variety of cell types and selective drug accumulation 
at target sites.37,38 Other authors working with MNPs – used 
in hyperthermia,39 cancer diagnosis and biodistribution 
studies,40 and cancer therapy41 – have reported such facile 
cellular uptake. The DOX-MNPs can be transported into 
tumor cells by a process called endocytosis or phagocyto-
sis, through either specific or nonspecific cellular uptake, 
depending on the surface properties of the MNPs.42 How-
ever, the exact mechanism of cellular uptake may be far 
more complicated than the current understanding, and 
further studies are clearly needed.
In vitro, the DOX-MNPs was found to show a higher 
apoptosis-inducing effect in the LLC cell line than free 
DOX. These results are in agreement with previous reports. 
Kohler et al43 reported that methotrexate-immobilized 
poly(ethylene glycol) MNPs induce higher   cytotoxicity 
in glioma cells than free methotrexate, depending on 
higher uptake and retaining its crystal structure in the 
cell cytoplasm. Chen et al44 reported that the application 
of 5-bromotetrandrine and MNP of Fe3O4 inhibited the 
expression of Bcl-2 protein and upregulated the expression 
of BAX and caspase-3 proteins in human leukemia K562/
A02 cells. Jiang et al45 reported expressions of multidrug 
resistance proteins MDR1, lung resistance-related protein, 
and P-glycoprotein were decreased. Therefore, MNPs may 
suppress tumor cell proliferation and induce apoptosis by 
blocking multiple pathways.
In vivo, the DOX-MNPs showed higher antitumor effi-
cacy than free DOX on subcutaneous LLC tumor-bearing 
models. The authors chose to administer only a single dose 
of DOX (10 mg/kg body weight) or an equivalent dose of 
DOX-MNPs to the tumor site. The tumor growth rate was 
not found to significantly decrease with free DOX treatment; 
however, the tumor growth rate was significantly decreased 
in the group treated with DOX-MNPs with an external 
magnetic field, and the rate of metastasis was also decreased. 
Meanwhile, the concentration of Fe3O4 particles inside tumor 
cells was found to increase when a simple external magnetic 
field was applied, indicating the concentration of DOX in the 
tumor was increased. These results were similar to previous 
results that stated only using an external magnetic field was 
effective. Widder et al46 demonstrated the utility of magnetic 
albumin microspheres in animal tumor models. Significantly 
greater responses, in terms of both tumor size and animal 
survival, were achieved with magnetic albumin microspheres 
than with DOX alone. Gupta and Hung47 demonstrated 
that the efficacy of magnetic microspheres in the targeted 
delivery of an incorporated drug is predominantly due to 
the magnetic effects, not the particle’s size or nonmagnetic 
holding. Smaller tumor volumes were found in the groups 
treated with DOX-MNPs under a magnetic field than in those 
receiving treatment without a magnetic field. Reasons for 
the higher antitumor activity may be higher concentration of 
DOX-MNPs in the tumor site, facile cellular uptake by tumor 
cells, and sustained drug release in the microenvironment. 
In this study, the DOX-MNPs were administered through a 
direct intratumoral injection to evade the RES; the external 
magnetic field may hold the nanoparticles in place rather than 
guiding or targeting the nanoparticles to the tumor site.
Conclusion
In summary, the authors constructed a PLGA-based polymeric 
nanocarrier coencapsulated with DOX and MNPs by a single 
emulsion evaporation method for intratumoral drug delivery. 
The nanoparticles supported sustained and steady release of 
DOX. Moreover, the drug release from the DOX-MNPs was 
pH sensitive, with a faster release rate in an acidic environment 
than in a neutral   environment. In vitro, the DOX-MNPs were 
readily internalized into tumor cells, and they induced a higher 
apoptosis rate. In vivo, the   DOX-MNPs showed higher rates 
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of antitumor activity than free DOX solution. Furthermore, 
applying an external magnetic field enhanced the antitumor 
activity of the DOX-MNPs, with smaller tumor volumes and 
lower rates of metastases incidence being exhibited. This work 
provides an exciting new modality for developing an effective 
drug delivery system.
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